Replies to post #13935 on Sorrento Therapeutics Inc (SRNE)

[dia76ca]

"Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced an increase of 53% year-over-year preliminary unaudited gross ZTlido sales in March. ZTlido sold $8.1 million in March 2022 compared to $5.3 million in March 2021. In 1Q2022, the preliminary unaudited gross sales for ZTlido are approximately $18.4 million, compared to $14.6 million in 1Q2021, representing a growth of 26%."

[1776club]

Need that a month. Only need some sales people that can...SELL! Wait, they are looking for 3 or 4 marketing people at the moment. New building almost complete and more cash out the door, I can hear the wind whistling down the halls along with the tumbleweed.

[Brandywhitneylady]

Like the $100 million in Stix sales? How is that going?

[XWAVXALMIMAN]

Dia, I have avoided the boards for a while but have been buying to average down. Why do we keep going down despite good news? When do you think we will go back to double digits if ever? Any news on the PSS lawsuit?